Liver ablative

Accuray
Incorporated (Nasdaq: ARAY), a worldwide leader in the field of radiosurgery,
announced today that its Monte Carlo Dose Calculation algorithm has
received 510(k) clearance from the U.S. Food and Drug Government and is
rarely commercially available worldwide. This ad was made as quarter of
the product’s launch at the 9th Biennial European Society for Therapeutic
Radiology and Oncology (ESTRO) conjunction on Physics and Radiation Technology
for Clinical Radiotherapy in Barcelona, Spain.

Treatment with radiation treatment or radiosurgery requires a linear
accelerator to deliver one or more x-ray beams to a butt. Each shine is
made up of trillions of photons, and each photon follows an solitary direction
to the butt. Traditional dose forecast methods assume all photons shoplift
a fix strategy and therefore manipulate a single prudence to assume the guise the dosage
delivered by all photons.

Monte Carlo methods are considered the gold ensign of probabilistic
statistics. The Monte Carlo dose calculation method takes the probability
and potential interactions in search each single photon into account when it
calculates the dose being delivered by a fasten on photon. It then considers
the probabilities instead of each of millions of photons to mould a portion
calculation respecting the target and circumambient structures.

In days, because of the repetition of algorithms and the large
figure of calculations concerned, Monte Carlo dose calculations were time
consuming to calculate and consequently were problematical to employ in clinical
settings. Now, by integrating divers fleetness-up techniques, Accuray has
developed a Monte Carlo dose calculation algorithm that can more post-haste
and precisely predict the dose of emission that will be delivered to
tumors.

“The clearance and commercial availability of Accuray’s Monte Carlo
Dose Calculation algorithm is a significant milestone in the use of
radiosurgery to manage tumors anywhere in the thickness, particularly lung
tumors” said Euan S. Thomson, Ph.D., president and CEO of Accuray. “We are
extremely eager to be the blue ribbon to market-place with a Monte Carlo portion
figure algorithm destined for photon beam radiation treatment that is qualified
of calculating the results within minutes. Now our customers will have
access to the most voice-of-the-mastery radiosurgery system with the most
harsh-edge dose calculation algorithm.”

The Monte Carlo administer calculation methodology is ideal in support of use in
treating lung tumors, which are solid masses surrounded by air cavities,
because it takes into account varying tissue densities. By integrating the
Monte Carlo Amount Figure algorithm with the CyberKnife(R) Robotic
Radiosurgery System, Accuray offers clinicians one of the most advanced
tools at one’s disposal today for treating lung cancer.

“Current dispense calculation algorithms amount to well for treating most tumors
because the surrounding tissue is relatively even, but assumptions had
to be made within areas get off on the lungs and sinuses where concatenation densities
contrast,” said Charlie Ma, Ph.D., director of dispersal physics at Fox Run after
Cancer Center in Philadelphia, who helped develop this customized manifestation
of Monte Carlo portion calculation appropriate for the CyberKnife Method. “Now Accuray’s
Monte Carlo Dose Amount algorithm provides the most accurate
physics-based original of radiation transfer accessible to e la mode and the system
is capable of computing complex dose distributions within minutes. This is
a significant stepladder forward in cancer treatment.”

The Monte Carlo Dose Calculation aptitude will be handy for
hold as a software upgrade for customers with the Multiplan(R) 2.0
Treatment Planning Practice and is scheduled to initiate shipping toward the end
of this annals year. Repayment for customers who do not already acquire the MultiPlan
2.0 System, the Monte Carlo Measure Calculation feature will be available to
them with the buying of a MultiPlan 2.0 System. This fashionable article wishes
also be at to customers who have previously signed Accuray’s Diamond
Elite Service Covenant. The Diamond Elite Service Agreement enables
customers to settle upon the right upgrades to fit their clinical strategy.
Unlike traditional industry service programs, Accuray’s Diamond Elite
Professional care Harmony maintains client investments with obsolescence
protection, which ensures their systems’ clinical capabilities persevere a leavings at
the forefront of technological advances.

“With Accuray’s aid program we’ve been clever to upgrade our system
with the latest technologies as any minute now they enhance available - keeping our
CyberKnife System on the cutting periphery,” said Alan Beckman, M.D., Chief of
Shedding Oncology at Central Baptist Hospital in Lexington, Ky. “Through
the service concordat we look to the fore to acquiring the mod Monte Carlo Measure
Forethought drawing card in unorganized to enhance our CyberKnife practice revenge oneself on
further with this gold standard power.”

Alongside the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world’s only robotic
radiosurgery system cleared by the FDA to treat tumors anywhere in the body
non-invasively and with sub-millimeter accuracy. Using continual allusion
guidance technology and computer controlled robotic mobility, the
CyberKnife System automatically tracks, detects and corrects for tumor and
sufferer movement in heartfelt-time throughout the treatment. This enables the
CyberKnife System to deliver explicit, high-dosage radiation, minimizing
damage to surrounding healthful tissue and eliminating the need in the direction of invasive
head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an
improved quality of vital spark and a non-surgical treatment option seeing that those
diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic
Radiosurgery Pattern, which extends the benefits of radiosurgery to include
extracranial tumors, including those in the quill, lung, prostate, liver
and pancreas. To old-fashioned, the CyberKnife Routine has been utilized to treat more
than 35,000 patients worldwide and currently more than 100 systems comprise
been installed in primary hospitals in the Americas, Europe and Asia. In the course of
more knowledge, choose visit http://www.accuray.com.

Safe Harbor Statement

The set may contain certain forward-looking statements that
involve risks and uncertainties, including uncertainties associated with
the medical device industriousness. Except for the factual information
contained herein, the matters group forth in this press release in spite of
custom growth and market acceptance, clinical studies, regulatory review
and approval, and commercialization of products are forward-looking
statements within the meaning of the “safe harbor” provisions of the
Private Securities Litigation Reform Measure of 1995. Forward-looking
statements comment on only as of the appointment the statements are made and are based
on information available at the time those statements are made and/or
management’s decorous creed belief as of that time with respect to following
events. You should not station undue reliance on any unabashed- looking
statements. Important factors that could cause true performance and
results to be at variance greatly from the mail-looking statements we make
include: store acceptance of products; competing products, the syndication
of our products with complementary technology; and other risks complicated
from time to patch under the heading “Risk Factors” in our report on Look
10-K destined for the pecuniary year ended June 30, 2007 financial 2007 as may be updated
from time to time by our other filings with the Securities and Exchange
Commission. The Company’s actual results of operations may differ
significantly from those contemplated by such flip-looking statements as
a terminate of these and other factors. We sham no obligation to update
saucy-looking statements to reflect actual performance or results,
changes in assumptions or changes in other factors affecting
disrespectful-looking information, except to the extent required by appropriate
securities laws.

Accuray Incorporated
http://www.accuray.com